What do Insider Trends Have to Say About Gilead Sciences, Inc. (GILD)?

Marco Green
December 7, 2017

The stock decreased 0.03% or $0.025 during the last trading session, reaching $73.265. The shares were sold at an average price of $74.64, for a total transaction of $1,119,600.00. ONEOK, Inc. (NYSE:OKE) has risen 23.81% since December 6, 2016 and is uptrending. It has underperformed by 16.38% the S&P500.

Recent trading patterns in the stock of Gilead Sciences, Inc.

GSA Capital Partners LLP lessened its holdings in shares of Gilead Sciences, Inc. About 2.93 million shares traded. TheStreet upgraded Gilead Sciences from a "c+" rating to a "b-" rating in a research report on Thursday, September 7th. The stock increased 1.12% or $0.76 during the last trading session, reaching $68.6. About 3.91 million shares traded. It has underperformed by 38.50% the S&P500.

Analysts await The Coca-Cola Company (NYSE:KO) to report earnings on February, 8. It also reduced Qiagen Nv stake by 198,000 shares and now owns 1.13M shares. After $0.50 actual EPS reported by The Coca-Cola Company for the previous quarter, Wall Street now forecasts -24.00% negative EPS growth. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company's stock valued at $378,000 after buying an additional 46 shares during the period. (NASDAQ:GILD). 400 are owned by Kings Point Cap. Microsoft Corp (NASDAQ:MSFT) was raised too. Therefore 68% are positive. On Tuesday, August 1 the stock rating was maintained by Stifel Nicolaus with "Hold". The stock has "Overweight" rating by Piper Jaffray on Thursday, November 5. The rating was maintained by Cowen & Co on Wednesday, November 16 with "Outperform". The rating was maintained by RBC Capital Markets with "Outperform" on Thursday, December 1. Robert W. Baird has "Buy" rating and $87.0 target. (NASDAQ:GILD) rating on Wednesday, October 5. On Friday, August 4 the stock rating was maintained by Oppenheimer with "Buy". Nuveen Asset Ltd holds 267,605 shares or 0.13% of its portfolio.

Investors sentiment decreased to 0.79 in Q2 2017. Its down 0.17, from 1.09 in 2017Q1. Hanson And Doremus Mngmt holds 0.09% or 1,621 shares. 499.72 million shares or 1.80% less from 508.89 million shares in 2017Q1 were reported. Lowe Brockenbrough & Co has 19,395 shares for 0.22% of their portfolio. The Platinum Investment Management Ltd holds 2.89 million shares with $204.52M value, up from 2.47 million last quarter.

The company reported its EPS on 9/29/2017. Driehaus Mgmt Ltd Liability Com has 7,327 shares. 49,317 are held by Front Barnett Assocs Ltd Liability. (NYSE:OKE) for 2,186 shares. Rudman Errol M accumulated 70,704 shares or 2.86% of the stock. Country Bancshares reported 122 shares. (NYSE:OKE). Motco holds 2,000 shares. (NASDAQ:GILD). Founders Securities Limited Liability Corporation holds 0.37% or 13,652 shares. Aspiriant owns 29,445 shares. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company's stock valued at $330,000 after buying an additional 32 shares during the period. Mawer Invest Ltd stated it has 565,570 shares. Of Toledo Na Oh owns 15,495 shares or 0.26% of their U.S. portfolio. (NASDAQ:GILD). Columbia Asset reported 3,681 shares. They expect $1.67 EPS, down 36.74% or $0.97 from last year's $2.64 per share. KO's profit will be $1.62 billion for 30.45 P/E if the $0.38 EPS becomes a reality.

Investors sentiment increased to 0.93 in Q2 2017. Its down 0.02, from 0.8 in 2017Q1. It improved, as 78 investors sold GILD shares while 538 reduced holdings. 110 funds opened positions while 462 raised stakes. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.18 by $0.02. Walter And Keenan Fincl Consulting Mi Adv has invested 0.14% in Gilead Sciences, Inc. Citigroup owns 912,833 shares for 0.06% of their portfolio. Shares of GILD have sank -11.65% in the past three monthswhile the S&P 500 has dropped -18.11% in that time. Thompson Siegel Walmsley Ltd holds 203,430 shares. Arizona State Retirement Sys reported 426,165 shares. Finally, Frontier Wealth Management LLC raised its holdings in Gilead Sciences by 10.7% in the 2nd quarter. Hudson Bay Capital Management Lp who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $95.24B market cap company. (NASDAQ:GILD). Moreover, Montecito Financial Bank has 0.24% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Jlb Assocs accumulated 113,997 shares. Mercer Cap Advisers, a New Jersey-based fund reported 8,179 shares. (NASDAQ:GILD) news were published by: Bizjournals.com which released: "With HIV infection rates soaring in South, Gilead pledges $100 million" on December 04, 2017, also Seekingalpha.com with their article: "Buy Gilead Now And Get Kite For "Free" published on November 27, 2017, Bizjournals.com published: "Gilead Sciences, University of Houston and others launch $100M initiative to ..." on December 05, 2017. (NASDAQ:GILD). Gideon Capital Advsrs holds 0.41% in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. It also upped Spdr S&P Midcap 400 Etf (MDY) stake by 5,831 shares and now owns 37,847 shares. (NASDAQ:GILD) which added $0.2 between open and close. Therefore 67% are positive. Bank of America maintained the shares of ESRX in report on Tuesday, June 7 with "Neutral" rating. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. The rating was maintained by UBS on Friday, April 29 with "Buy". Gilead Sciences had 107 analyst reports since July 29, 2015 according to SRatingsIntel. (NASDAQ:GILD) earned "Outperform" rating by Credit Suisse on Wednesday, February 3. The company was maintained on Wednesday, August 31 by Jefferies. Gilead Sciences has $137 highest and $7200 lowest target. On Thursday, October 19 the stock rating was maintained by Leerink Swann with "Market Perform". Deutsche Bank downgraded the shares of ESRX in report on Monday, February 22 to "Sell" rating. As per Friday, October 6, the company rating was maintained by Morgan Stanley. Maxim Group restated a "hold" rating on shares of Gilead Sciences in a research report on Monday, August 28th. (NASDAQ:GILD) on Tuesday, July 11 with "Hold" rating.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER